Table 1 Characteristics of autologous... | American Society of Hematology

Table 1

Characteristics of autologous transplantation patients

Patient ID	Age/sex	Diagnosis	Mobilization protocol	WBCs pre/post G-CSF, × 10⁹/L	CD34⁺ cells/μL
19	72/F	MM	Modified HD Cyclo 2 g/m²	7/38	7
30	55/M	NHL/DLCL relapse	ICE/PEG	6/40	NA
31	48/F	NHL/DLCL	ICE/PEG	5/13	27
32	56/M	MM	HD Cyclo	10/11	33
43	53/M	Peripheral T-cell lymphoma relapse	ICE	11/11	56
46	48/M	NHL/DLCL	RICE	7/48	29
48	39/M	MM	HD Cyclo	9/42	216
50	26/F	HD relapse	ICE	7/8	7
59	56/M	MM	HD Cyclo	12/13	64
66	61/F	MM	HD Cyclo	7/16	101
67	53/F	MM	HD Cyclo	8/32	198

Patient ID	Age/sex	Diagnosis	Mobilization protocol	WBCs pre/post G-CSF, × 10⁹/L	CD34⁺ cells/μL
19	72/F	MM	Modified HD Cyclo 2 g/m²	7/38	7
30	55/M	NHL/DLCL relapse	ICE/PEG	6/40	NA
31	48/F	NHL/DLCL	ICE/PEG	5/13	27
32	56/M	MM	HD Cyclo	10/11	33
43	53/M	Peripheral T-cell lymphoma relapse	ICE	11/11	56
46	48/M	NHL/DLCL	RICE	7/48	29
48	39/M	MM	HD Cyclo	9/42	216
50	26/F	HD relapse	ICE	7/8	7
59	56/M	MM	HD Cyclo	12/13	64
66	61/F	MM	HD Cyclo	7/16	101
67	53/F	MM	HD Cyclo	8/32	198

MM indicates multiple myeloma; NHL, nonHodgkin lymphoma; DLC, diffuse large cell lymphoma; HD, Hodgkin disease; HD Cyclo, high-dose cyclophosphamide; ICE, ifosfamide, carboplatin, and etoposide; and RICE, rituximab and ICE.

View Large

This Feature Is Available To Subscribers Only